Background Idiopathic pulmonary fibrosis (IPF) is one of a number of interstitial lung diseases (ILDs) that result in extensive and chronic pulmonary fibrosis. In IPF pathology, immunological dysfunction has been identified as a contributing factor to the ongoing fibrotic process, implicating cells and mechanisms of both the innate and humoral immune response. Due to the complex and diverse range of cells and mediators involved in IPF, the pathology is still poorly understood. Evidence of complement activation through the classical pathway in IPF lungs implies a role for IgG in the pathology. The active IgG in IPF may be autoreactive in nature, as IgG that target antigens of alveolar epithelial cells have been. Two autoantibodies in IPF, anti-periplakin IgG and anti-Hsp72 IgG, have been associated with poorer prognoses in IPF patients. The association of anti-Hsp72 IgG with IPF patient outcomes has not been validated and little work has been done to study the underlying mechanisms of autoantibodies in IPF pathogenesis. Hypothesis Anti-Hsp72 IgG is associated with poorer outcomes in IPF, and may induce alveolar macrophages to exhibit a pro-fibrotic phenotype. Aims The aims were to:  Optimise an ELISA for anti-Hsp72 IgG detection and determine any association of anti-Hsp72 IgG with IPF patient outcomes  Determine the location of anti-Hsp72 IgG producing cells and detect if Hsp72-IgG complexes are present in IPF patients’ lungs  Explore a potential underlying pro-fibrotic mechanism through which anti-Hps72 IgG modulates macrophage function. Results The presence of anti-Hsp72 IgG was determined in ILD patient and healthy control bronchoalveolar lavage fluid (BALf) and serum. A novel anti-Hsp72 IgG ELISA was developed and optimised and then compared against a commercial anti-Hsp72 IgGAM ELISA which became available during the PhD. Progression in IPF was defined by a decrease of ≥10% vital capacity (VC) over twelve months. Serum anti-Hsp72 IgG(AM) did not associate with changes in VC over 12 months. In contrast, BALf anti-Hsp72 IgG(AM) concentrations were elevated in IPF non-progressors. Patients with high BALf anti-Hsp72 IgGAM, had improved survival compared patient with low anti-Hsp72 IgGAM (adjusted HR 0.39, 95% CI 0.16-0.92; p=0.032) In contrast there was no association between anti-Hsp72 IgG and survival. Detection of anti-Hsp72 IgG subtypes in the serum and BALf of IPF patients revealed no significant difference in anti-Hsp72 IgG subtype detection levels between progressors and non-progressors. BALf anti-Hsp72 IgG1 levels were associated with a significantly lower rate of decline in VC over twelve months than patients with no detectable anti-Hsp72 IgG1. The presence of Hsp72-IgG complexes was confirmed by detection in purified IgG from IPF patient BALf. Immuno-histological detection of C4d deposition in the lungs of IPF patients coincided in areas of Hsp72 expression in alveolar epithelium. Summary These findings do not validate serum and-Hsp72 IgG as a biomarker for IPF. They support a role for anti-Hsp72 IgG in IPF, but associate with decreased rates of lung function decline and increased patient survival. Data also suggests that the decreased rate of decline may be related to specific anti-Hsp72 IgG subtype expression. The immune-histological data further suggests that anti-Hsp72 IgG may be targeting Hsp72 expressed by lung epithelium. Therefore these findings support a role for immunological dysfunction in IPF, but further work is required to determine the underlying mechanism.

Human pluripotent stem cells (hPSCs) such as, human embryonic stem cells (hES) and human induced pluripotent stem cells (hiPS) are a valuable resource to generate bespoke cell types for a number of therapeutic applications involving cell therapy, drug screening and disease modelling. The overarching goal of this project was to generate a set of transgenic tools by gene targeting and genetic modification of hESCs for applications in stem cell biology such as the in vitro isolation, analyses and derivation of lineage specific cell types. The transgenic tools generated in this study were designed and tested in particular for the human 3rd pharyngeal pouch epithelium (3PPE) like cells and its derivatives, namely the thymus and parathyroid, which are key organs involved in T-cell development and calcium homeostasis respectively. The forkhead transcription factor FOXN1 is considered a master regulator of the development of the thymic epithelium (TEC), the major functional component of the thymic stroma, which is intimately involved in T-cell differentiation. So, to facilitate the prospective isolation of FOXN1 expressing TECs, gene targeting was employed to place a fluorescent reporter and a lineage selection antibiotic resistance gene under the direct control of the endogenous FOXN1 promoter. To date, I have not been able to detect either the fluorescent reporter, or FOXN1 expression using published directed differentiation protocols, but only what can be deemed as precursors expressing the cytokeratin K5 and other markers associated with the development of the thymus and parthyroid from 3PPE. The lack of endogenous FOXN1 activation was observed in both the unmodified parent and the targeted FOXN1 knock-in human ES lines. Further, over-expression of FOXN1 cDNA during the differentiation protocol did not result in the activation of endogenous FOXN1. So, the results evinced in this study could be due to a number of reasons such as, technical issues associated with transference of the published protocols to the cell lines used in this study, differences in hESC lines, and effects of different hESC culture methods and practices. The homeobox gene HOXA3 is expressed in the 3PPE during development. So, a HOXA3 transgenic reporter hESC line could be an invaluable tool for prospective isolation of in vitro derived 3PPE like cells. The reporter was generated by Piggy Bac transposase mediated transposition of a HOXA3 containing Bacterial Artificial Chromsome (BAC) in the FOXN1 knock-in human ES line. To date, this is biggest reported cargo that has been successfully transposed in human ESCs. Moreover, this is the first lineage specific double reporter transgenic hESC line that has been reported for this lineage. This HOXA3 reporter line was then used to isolate and enrich for HOXA3 expressing 3PPE like cells with very high efficiencies during the directed differentiation of hESCs, thus demonstrating the key objective of this transgenic hESC line for this study. In a novel parallel approach, I have conceived, designed and generated transgenic hESCs lines capable of inducible and constitutive over-expression of key transcription factors involved in the development of 3PPE and its derivatives, the thymus and parathyroid. The objective of the said over-expression hESC lines was to interrogate if such a system could elicit morphological and gene expression changes in hESCs following over-expression. By testing the chosen panel of transcription factors in hESCs, I was able to detect cells expressing FOXN1 and GCMB, which are key markers of TECs and PTECs. Further, I have isolated an expandable population of cells expressing markers analogous to their in vivo counterpart found in the 3PPE of a developing mouse embryo around E9.0. The in vivo potency of these in vitro derived 3PPE like cells is yet to be ascertained. Nevertheless, transgenic constructs generated in this experiment could also be tested during future attempts at the differentiation of hESCs to TECs and PTECs, and also used as a basis for future studies involving the direct conversion of patient specific fibroblasts to 3PPE like cells and its derivatives. In summary, several transgenic tools developed in this project, namely the FOXN1 knock-in transgenic hESC line, FOXN1-HOXA3 double transgenic hESC line, over-expression 3PPE transgenes and hESC transgenic lines, and results from the deployment of these tools provide a foundation, from which protocols to generate functional TECs and PTECs can be refined and optimised. These transgenic hESC lines also provide a tractable model, which could be used to interrogate the development of human TECs and PTECs from human 3PPE, and identify hitherto unknown early events in their development in an in vitro reductionist setting.

A presente dissertação discute o repasse cambial para o IPCA na economia brasileira durante o período compreendido entre janeiro de 1999 e dezembro de 2007. A ampla maioria dos trabalhos que versam sobre este tema aborda a redução do repasse após a adoção do regime de metas de inflação e/ou tem como único foco o impacto das desvalorizações cambiais no aumento dos índices de preços. Este trabalho, por outro lado, aborda de maneira explícita o papel da valorização do Real sobre a variação do IPCA no período recente, configurando o que denominamos de repasse cambial reverso. Para tanto, estimamos o repasse cambial por meio de um modelo de vetores auto-regressivos tanto para o referido período (1999-2007), quanto para outros dois recortes temporais: entre janeiro de 1999 e junho 2003 (amostra 1), período no qual se verifica uma tendência de desvalorização cambial e aumento de preços; e de julho de 2003 a dezembro de 2007 (amostra 2), período caracterizado pelo processo inverso, de valorização da taxa de câmbio e de cumprimento das metas de inflação na maioria dos anos. Os principais resultados foram: (i) no longo prazo os coeficientes de repasse cambial para o IPCA para as duas amostras foram superiores àqueles verificados para o período completo; e (ii) o repasse estimado para a amostra 2 foi bem elevado, ainda que inferior àquele obtido para a amostra 1. Estes resultados reforçam o argumento de que a taxa de câmbio desempenhou um papel proeminente no controle da inflação no período 2003-2007. / The present dissertation discusses the exchange rate pass-through to the headline inflation index, i.e. extensive national consumer price index (IPCA) in the Brazilian economy between January 1999 and December 2007. The vast majority of works dealing with this issue addresses the reduction of the pass-through after the adoption of the inflation targeting regime and / or focuses on the impact of exchange rate devaluation over the price index. This work, alternatively, discusses the role of the Brazilian currency appreciation in the recent period, resulting in what was labeled as reverse exchange rate pass-through. Thus, we have used a model of auto-regressive vectors to estimate the exchange rate pass-through for the full period (1999-2007), and for two other periods: between January 1999 and June 2003 (sample 1), during which there was a tendency for devaluation and increase in domestic prices, and from July 2003 to December 2007 (sample 2), that was a period characterized by the reverse process, that is exchange rate appreciation and in the most cases the achieving of the inflation targets. The main results were: (i) in the long run the exchange rate pass-through coefficients to IPCA of the two samples were higher than those observed for the full period, and (ii) the pass-through estimated for the sample 2 was very high, despite the fact that it was lower than that obtained for the sample 1. Those results reinforce the argument that the exchange rate played a prominent role in controlling inflation in the period 2003-2007.

This thesis is based on the basic informations of the company,the marketing situational analysis is broken down in the internal and external analysis using PEST analysis, analysis of product portfolio - the Boston Matrix, Porter's five forces model and SWOT analysis. There is a description of the current business developments and current status. This thesis describes the opportunities, skills and resources of the company. Further I have specified the basic mission and objectives, market segmentation,targeting and positioning. The conclusion contains the marketing strategies according to the product strategies in pricing, distribution strategy, promotion strategy and the strategy according to market trends.

The goal of the diploma thesis is to analyze the situation of behavioral targeted advertising in the Czech Internet market, assess its potential in the future and evaluate the effectiveness of behavioral targeting on the Czech market. This thesis is focused first on the Internet advertising market, media planning, explanation of selected targeting approaches and on detailed description of the behaviorally targeted ads including the online privacy issue. In the practical part analysis of the behavioral targeted advertising on the Czech market through expert interviews and evaluation of the effectiveness of behavioral targeting on an example of an advertising campaign of selected company is to be found.

This thesis investigates the role of the exchange rate and interest rate channels in the monetary transmission mechanism in Ukraine. The responses on the domes- tic as well as Russian economy shocks are estimated using the Vector Autoregression Model with block-exogeneity restriction. Monetary transmission did not prove to be strongly effective via neither of the estimated channels, although the exchange rate channel demonstrates the results which are more in line with the economic theory. In addition, the exchange rate channel shows the higher and more significant pass through. Further, we estimate the importance of the shocks of both home and for- eign economies for the domestic variables deviations using variance decomposition technique. The relevance of the Russian shocks in fluctuations of home variables is found out. The current estimation of the transmission mechanism is relevant due to the planned inflation targeting regime implementation in Ukraine which requires understanding of that processes in the economy. 1

Uma nova alternativa para o tratamento do câncer foi proposta em estudos anteriores, consistindo no uso de uma nanoemulsão lipídica como transportadora de agentes quimioterápicos às células neoplásicas. A redução da toxicidade da quimioterapia promovida pelo direcionamento específico de quimioterápicos às células tumorais nos levou a testar o potencial de aplicação do sistema de nanopartículas lipídicas na terapêutica combinada do paclitaxel com a sinvastatina, um agente hipolipemiante que pode ser empregado como coadjuvante no tratamento do câncer. Nos dias 11, 14 e 19 após a inoculação de células de melanoma B16F10, camundongos C57BL/6J receberam pela via intraperitoneal soluções de oleato de paclitaxel associado à nanoemulsão lipídica 17,5µmol/kg (Nano-paclitaxel), formulação comercial do paclitaxel 17,5µmol/kg, nanoemulsão lipídica (Nanoemulsão) e solução salina (Controle). A sinvastatina 50mg/kg/dia foi administrada por gavagem do 11° ao 19° dia após a inoculação do tumor em um dos grupos de animais tratados com o Nano-paclitaxel (Nano-paclitaxel + Sinva), no grupo tratado com a formulação comercial do paclitaxel (Paclitaxel + Sinva) e como monoterapia (Sinva). Camundongos Balb-c saudáveis receberam os mesmos tratamentos para avaliação dos possíveis efeitos tóxicos dos diferentes tratamentos. A terapia combinada Nano-paclitaxel + Sinva apresentou toxicidade negligível em comparação com a terapia combinada Paclitaxel + Sinva que provocou perda de peso e mielossupressão nos animais. Nos animais portadores de tumor, o tratamento Nano-paclitaxel + Sinva inibiu 95% do crescimento tumoral, comparado à inibição de 44% promovida pelo tratamento Paclitaxel + Sinva. Além disso, apenas 37% dos animais portadores de melanoma submetidos ao tratamento com Nano-paclitaxel + Sinva apresentaram metástases, em contraste com 90% dos tratados com Paclitaxel + Sinva. A probabilidade de sobrevida também foi maior nos camundongos tratados com o Nano-paclitaxel + Sinva em comparação aos tratados com Paclitaxel + Sinva. A análise de amostras de tumores por citometria de fluxo mostrou que somente nos grupos de animais tratados com Sinva, Nano-paclitaxel ou com a combinação Nano-paclitaxel + Sinva houve aumento na expressão de p21 em comparação ao grupo Controle. Da mesma forma, apenas nos grupos Sinva e Nano-paclitaxel + Sinva houve redução na expressão de ciclina D1 em comparação ao grupo Controle. O teste de viabilidade celular com rodamina 123 mostrou despolarização da membrana mitocondrial com redução no número de células tumorais viáveis em todos os grupos de tratamentos em comparação aos grupos Nanoemulsão e Controle. A avaliação histológica dos tumores demonstrou que os grupos Nanoemulsão e Controle apresentaram alta densidade de células tumorais, diferentemente dos demais grupos de tratamento e que apenas os tumores do grupo Nano-paclitaxel + Sinva apresentaram aumento na presença de fibras de colágeno tipo I e III. Em comparação ao grupo Controle, os tumores dos grupos Sinva, Paclitaxel + Sinva, Nano-paclitaxel e Nano-paclitaxel + Sinva apresentaram redução na expressão imunohistoquímica de ICAM, MCP-1 e MMP-9 sendo que o grupo Nano-paclitaxel + Sinva apresentou a menor porcentagem de área marcada positivamente para a MMP-9. A terapia combinada com Nano-paclitaxel + Sinva é menos tóxica e mais efetiva na inibição do crescimento tumoral do que a mesma terapia com a formulação comercial do paclitaxel. / In previous studies we have proposed a novel approach for cancer treatment consisting of the use of a lipid nanoemulsion as a vehicle to direct chemotherapeutic agents to neoplastic cells. Reduction of chemotherapy toxicity promoted by specific targeting of antineoplastic agents to tumor cells led us to test the application of the lipidic nanoparticle system in combined treatment with paclitaxel and simvastatin, a cholesterol-lowering drug that can be used as coadjuvant in cancer treatment. On days 11, 14 and 19 after B16F10 melanoma cells inoculation, C57BL/6J mice were intraperitoneally injected with paclitaxel oleate associated to the lipidic nanoemulsion 17.5 µmol/kg (Nano-paclitaxel), commercial formulation of paclitaxel 17.5 µmol/kg, lipidic nanoemulsion (Nanoemulsion) or saline solution (Control). Simvastatin 50 mg/kg/day was administered by gavage from days 11 to 19 after tumor inoculation in one group of animals treated with Nano-paclitaxel (Nano-paclitaxel + Simva), in the group treated with commercial formulation of paclitaxel (Paclitaxel + Simva) and as monotherapy (Simva). Evaluation of possible toxic effects of the treatments was accessed in healthy Balb-c mice. Combined therapy with Nano-paclitaxel + Simva showed negligible toxicity as compared with the combination of Paclitaxel + Simva which resulted in animal weight loss and myelosuppression. In tumor-bearing animals, treatment with Nano-paclitaxel + Simva resulted in a remarkable tumor growth inhibition rate of 95%, compared to a 44% inhibition rate promoted by treatment with Paclitaxel + Simva. Moreover, only 37% of melanoma bearing animals treated with Nano-paclitaxel + Simva developed metastasis, in contrast to 90% of those treated with Paclitaxel + Simva. Survival rates were also higher in mice treated with Nano-paclitaxel + Simva in comparison to Paclitaxel + Simva treated animals. Analysis of tumor samples by flow cytometry showed that only animals treated with Simva, Nano-paclitaxel or Nano-paclitaxel + Simva increased the expression of p21 in comparison to Control group. Also, tumors from animals treated with Simva or Nano-paclitaxel + Simva presented a decrease in the expression of cyclin D1 in comparison to Control group. Cell viability test with rhodamine 123 showed mitochondrial membrane depolarization with reduction of tumor viable cells in all treatment groups in comparison to Nanoemulsion and Control groups. The histological study revealed that in contrast to drugs treated groups, tumors from Nanoemulsion and Control groups presented high tumor cell density and only Nano-paclitaxel + Simva treated animals presented tumors with increased presence of collagen fibers I and III. In comparison to Control group, tumors from groups Simva, Paclitaxel + Simva, Nano-paclitaxel and Nano-paclitaxel + Simva showed a reduction in immunohistochemical expression of ICAM, MCP-1 and MMP-9 and the group Nano-paclitaxel + Simva presented the lowest percentage of area positively stained for MMP-9. Combined therapy with Nano-paclitaxel + Simva was less toxic and more effective in promoting tumor growth inhibiton than the same combined therapy with the commercial formulation of paclitaxel.

Este trabalho descreve os requisitos para definição, implantação, manutenção e melhoria de sistemas de gestão de energia no ambiente industrial com um enfoque sistemático no que se refere às rotinas de melhoria contínua para eficiência energética. Para tanto, propôs-se a estruturação de uma plataforma automatizada visando o monitoramento, verificação e gerenciamento de recursos energéticos compatível com um sistema de gestão de energia normatizado, incluindo os requisitos de uso e consumo de energia, além do monitoramento, documentação, comunicação, melhores práticas de projeto, aquisição de equipamentos, sistemas, processos e recursos humanos envolvidos no desempenho energético. A estratégia de análise do uso da energia proposta neste trabalho baseou-se na metodologia de monitoramento e gestão de índices que consiste em uma abordagem sistemática na utilização de recursos energéticos objetivando alcançar o melhor resultado econômico através da gestão permanente do consumo de energia. Além disso, propôs-se a inclusão dessa metodologia como um procedimento na fase de planejamento da norma ISO50001, a qual estabelece os conceitos para a implantação de sistemas de gestão de energia. Visando integrar as ferramentas associadas a este cenário, esta plataforma contempla o uso de um sistema de supervisão associado a um aplicativo (Soft-PLC) que executa a aplicação de controle do uso de energia em um ambiente industrial com automação distribuída compatível com a norma IEC61131. O projeto do aplicativo de controle do uso de energia foi conduzido adotando-se diferentes linguagens de programação definidas na IEC para executar todos os procedimentos de medição, monitoração e gestão exigidos pelo sistema, incluindo análise comparativa com as “melhores práticas”, uso de tecnologias inovadoras, abordagem de produto e serviço, auditoria energética e conformidade com marcos regulatórios. Os resultados decorrentes da adoção de uma plataforma baseada em automação para o gerenciamento energético incluem elevada flexibilidade, adaptabilidade e usabilidade do sistema. Além disso, um projeto de automação neste cenário de plataforma aberta tende a apresentar menores custos de desenvolvimento e implantação. / This work describes the requirements for the definition, implementation, maintenance and improvement of energy management systems in the industrial environment with a systematic approach concerning continuous improvement routines for energy efficiency. For this purpose, it was proposed the establishment of a framework based on automation to implement monitoring, verification and management of energy resources compatible with a standardized energy management system, including requirements for energy use and consumption, in addition to monitoring, documentation, communication, project best practices, equipment acquisition, systems, processes and human resources involved in energy performance. The strategy of energy use analysis proposed in this work is based on the methodology of monitoring and targeting that consists of a systematic approach in the use of energy resources in order to achieve the best economic result through the permanent management of energy consumption. Furthermore, this work includes that system as a procedure in the planning phase of ISO50001 standard which establishes the concepts for energy management systems implementation. In order to aggregate all tools associated to this scenario, this paper proposes the use of a supervisory tool integrated to a real-time software (Soft-PLC) that runs the control application and a factory floor distributed system automation hardware in an IEC61131 compatible environment. The project of the control application of energy use was conducted using different programming languages defined in IEC to perform all the procedures of measurement, monitoring and management required by the system, including comparative analysis with the "best practices", use of innovative technologies, product and service approach, energy audit and compliance with regulatory milestones. The expected results of adopting an automation-based platform for energetic management include system flexibility, adaptability and usability. Besides, a project of automation in this scenario of open platform tends to introduce lower development and deployment costs.

Stroke is the 5th leading cause of death and the leading cause of disability in the United States, but there are only two available therapies, tissue plasminogen activator and endovascular thrombectomy. As both therapies focus on removal of the clot, the subsequent pathologic processes, i.e. inflammation, cerebrovascular breakdown, ATP depletion, etc. are left untreated, contributing to worsened patient outcome. Many clinical trials have unsuccessfully attempted to address these mechanisms. The blood-brain barrier (BBB), a system of non-fenestrated endothelial cells, extracellular matrix, and astrocytic endfeet, is significantly impacted after ischemic stroke in its role of preventing the free movement of proteins from the blood into the brain. In fact, BBB dysfunction is viewed as one of the major facilitators of damage following ischemic stroke, leading to increased infarct volumes and worsened patient outcomes. Interestingly, a family of endothelial integrins, the b1 integrins, have been shown to regulate tight junction proteins preventing the free movement of molecules. When expression of the tight junctions are decreased, this results in increased BBB permeability. To test this concept, our laboratory has previously shown the knockout of the particular β1 integrin, α5β1, is neuroprotective following ischemic stroke through BBB stabilization. To determine if therapeutically targeting integrin a5b1 was feasible, we first determined if brain integrin a5b1 expression increases after experimental mouse ischemic stroke model, specifically tandem/transient common carotid artery/middle cerebral artery occlusion. We found that integrin a5b1 does increase acutely, by post-stroke day (PSD)2, and continued in an exponential fashion through PSD4. Next, we determined if integrin a5b1 was therapeutically accessible by systemic treatment (i.e. intraperitoneal or intravenous) by being located on the inside (luminal surface) of vasculature. We found that location of integrin a5b1 was dependent on the area relative to the stroke injury. The core, or area of direct impact, demonstrated expression of integrin a5b1 on the outside vasculature (abluminal surface), while per-infarct expression was localized to the lumen. Lastly, to determine the activity of integrin a5b1 following ischemic stroke, we showed that the potential ligands (binding partners), plasma fibronectin, fibrinogen, and amyloid-b, do not bind integrin a5b1 after ischemic stroke. Next, we determined the therapeutic potential of targeting integrin a5b1 with the small peptide, ATN-161. ATN-161 has undergone clinical trials in solid tumors, with limited side effects reported. First, we determined that intraperitoneal (IP) injection of ATN-161 was safe after ischemic stroke, showing no changes in heart rate, pulse distention (blood pressure), or body temperature. Next, we found that IP administration of ATN-161 after experimental ischemic stroke reduced infarct volumes, edema, and functional deficit. Furthermore, these results were due to reduction of BBB permeability and anti-inflammatory effects. Interestingly, ATN-161 reduced cytokine production, prevented leukocyte infiltration, and leukocyte recruitment. Collectively, these results suggest that targeting integrin a5b1 with ATN-161 is 1) feasible, 2) safe and 3) effective, suggesting that ATN-161 may be a novel therapeutic treatment for ischemic stroke.

La compréhension des mécanismes régissant la recombinaison méiotique chez le blé tendre (Triticum aestivum L.) devient essentielle puisqu’elle est le levier principal utilisé par les sélectionneurs pour le brassage génétique et obtenir de nouvelles variétés élites comportant des introgressions de régions d’intérêt provenant de ressources génétiques exotiques. A cette fin, l’utilisation chez le blé tendre d’une nouvelle biotechnologie de ciblage de la recombinaison méiotique développée chez la levure par la société Meiogenix semble être prometteuse. Cette biotechnologie, nommée SpiX, fait intervenir un domaine protéique de liaison à l’ADN couplé à la protéine SPO11 responsable des cassures double-brins de l’ADN, initiatrices de la recombinaison méiotique ou crossovers (CO). Le développement d’une nouvelle technique de conservation des embryons immatures a permis d’améliorer les conditions de transformation par biolistique du blé tendre pour l’application de la technologie SpiX. L’exploitation de la séquence du génome du blé a permis d’isoler les gènes codant pour les protéines SPO11 du blé tendre. La complémentation hétérologue inédite de mutants pour les protéines SPO11 d’Arabidopsis thaliana avec les orthologues ainsi découverts chez le blé tendre montre leur grande conservation de séquence et de fonction au sein des plantes et leur potentielle fonctionnalité pour la biotechnologie SpiX. Enfin le test de différents domaines de liaison à l’ADN et de différentes cibles le long du chromosome 3B de blé tendre montre que la biotechnologie SpiX requiert des ajustements en fonction de l’espèce chez laquelle celle-ci doit fonctionner. Ces résultats sont ainsi l’opportunité de lever un premier voile sur le ciblage de la recombinaison méiotique chez une espèce de grande culture et de mieux comprendre les mécanismes de détermination des sites de cassures double-brins initiatrices de la recombinaison méiotique chez le blé tendre. / Understanding the mechanisms governing meiotic recombination in bread wheat (Triticum aestivum L.) is essential since it is the main tool used by breeders for genetic admixing and obtaining new elite varieties with introgression of regions of interest from exotic genetic resources. To this end, the use in bread wheat of a new biotechnology targeting meiotic recombination developed in yeast by Meiogenix seems to be promising. This biotechnology, named SpiX, involves a DNA-binding domain fused to the SPO11 protein responsible for DNA double-strand breaks, initiating meiotic recombination or crossovers (CO). The development of a new conservation protocol for wheat immature embryos has improved the conditions for bread wheat transformation through biolistic, and thus for the application of SpiX technology. The exploitation of the wheat genome sequence made it possible to isolate the bread wheat genes for SPO11 proteins. A novel heterologous complementation of Arabidopsis thaliana mutants for SPO11s with the bread wheat orthologous freshly discovered shows their great conservation of sequence and function within plants and their potential functionality for SpiX biotechnology. Finally, the testing of different DNA-binding domains and different targets along bread wheat 3B chromosome shows that SpiX biotechnology requires adjustments depending on the species in which it has to function. These results are the opportunity to uncover the targeting of meiotic recombination in a widely cultivated crop species and to understand the mechanisms determining sites for double-strand breaks prior to meiotic recombination in wheat.